tiprankstipranks
Enliven Therapeutics, Inc. (ELVN)
NASDAQ:ELVN
US Market
ELVN
Enliven Therapeutics
RESEARCH TOOLSreports
Want to see ELVN full AI Analyst Report?

Enliven Therapeutics (ELVN) Stock Forecast & Price Target

344 Followers
See the Price Targets and Ratings of:

ELVN Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Enliven
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELVN Stock 12 Month Forecast

Average Price Target

$64.56
▲(34.18% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Enliven Therapeutics in the last 3 months. The average price target is $64.56 with a high forecast of $80.00 and a low forecast of $55.00. The average price target represents a 34.18% change from the last price of $48.11.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","81":"$81","30.75":"$30.8","47.5":"$47.5","64.25":"$64.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.55555555555556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$64.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,30.75,47.5,64.25,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.76,51.16307692307692,53.566153846153846,55.96923076923077,58.37230769230769,60.77538461538462,63.178461538461534,65.58153846153846,67.98461538461538,70.3876923076923,72.79076923076923,75.19384615384615,77.59692307692308,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.76,49.975042735042734,51.19008547008547,52.40512820512821,53.62017094017094,54.83521367521367,56.05025641025641,57.265299145299146,58.48034188034188,59.69538461538461,60.910427350427355,62.125470085470084,63.34051282051282,{"y":64.55555555555556,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.76,49.239999999999995,49.72,50.199999999999996,50.68,51.16,51.64,52.12,52.6,53.08,53.56,54.04,54.519999999999996,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.79,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$80.00Average Price Target$64.56Lowest Price Target$55.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on ELVN
Dara Azar
Stifel Nicolaus
Stifel Nicolaus
$60→$80
Buy
66.29%
Upside
Reiterated
07/01/26
Enliven price target raised to $80 from $60 at StifelEnliven price target raised to $80 from $60 at Stifel
JonesTrading Analyst forecast on ELVN
Boris Peaker
JonesTrading
JonesTrading
$45→$70
Buy
45.50%
Upside
Reiterated
06/29/26
Enliven price target raised to $70 from $45 at JonesResearchEnliven price target raised to $70 from $45 at JonesResearch
Jefferies Analyst forecast on ELVN
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$59
Buy
22.64%
Upside
Reiterated
06/15/26
Jefferies Remains a Buy on Enliven Therapeutics (ELVN)
Guggenheim Analyst forecast on ELVN
Michael Schmidt
Guggenheim
Guggenheim
$80
Buy
66.29%
Upside
Reiterated
06/12/26
Analysts' Top Healthcare Picks: Amgen (AMGN), Enliven Therapeutics (ELVN)
LifeSci Capital Analyst forecast on ELVN
Sam Slutsky
LifeSci Capital
LifeSci Capital
$60
Buy
24.71%
Upside
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN) and Oncolytics Biotech (NASDAQ: ONCY)
TD Cowen Analyst forecast on ELVN
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/11/26
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Invivyd (IVVD)
Goldman Sachs Analyst forecast on ELVN
Salveen Richter
Goldman Sachs
Goldman Sachs
$41→$59
Buy
22.64%
Upside
Reiterated
06/04/26
Analyst Raises Price Target to $59 and Reaffirms Buy on ELVN-001’s Differentiated CML Opportunity
Mizuho Securities Analyst forecast on ELVN
Salim Syed
Mizuho Securities
Mizuho Securities
$45→$62
Buy
28.87%
Upside
Reiterated
06/02/26
Mizuho Securities Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)
H.C. Wainwright Analyst forecast on ELVN
Robert Burns
H.C. Wainwright
H.C. Wainwright
$56
Buy
16.40%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN), Molina Healthcare (NYSE: MOH) and Aldeyra Therapeutics (NASDAQ: ALDX)
Clear Street Analyst forecast on ELVN
Kaveri Pohlman
Clear Street
Clear Street
$36→$55
Buy
14.32%
Upside
Reiterated
04/27/26
Enliven price target raised to $55 from $36 at Clear StreetEnliven price target raised to $55 from $36 at Clear Street
BTIG Analyst forecast on ELVN
Justin Zelin
BTIG
BTIG
$45
Buy
-6.46%
Downside
Reiterated
08/14/25
BTIG Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on ELVN
Dara Azar
Stifel Nicolaus
Stifel Nicolaus
$60→$80
Buy
66.29%
Upside
Reiterated
07/01/26
Enliven price target raised to $80 from $60 at StifelEnliven price target raised to $80 from $60 at Stifel
JonesTrading Analyst forecast on ELVN
Boris Peaker
JonesTrading
JonesTrading
$45→$70
Buy
45.50%
Upside
Reiterated
06/29/26
Enliven price target raised to $70 from $45 at JonesResearchEnliven price target raised to $70 from $45 at JonesResearch
Jefferies Analyst forecast on ELVN
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$59
Buy
22.64%
Upside
Reiterated
06/15/26
Jefferies Remains a Buy on Enliven Therapeutics (ELVN)
Guggenheim Analyst forecast on ELVN
Michael Schmidt
Guggenheim
Guggenheim
$80
Buy
66.29%
Upside
Reiterated
06/12/26
Analysts' Top Healthcare Picks: Amgen (AMGN), Enliven Therapeutics (ELVN)
LifeSci Capital Analyst forecast on ELVN
Sam Slutsky
LifeSci Capital
LifeSci Capital
$60
Buy
24.71%
Upside
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN) and Oncolytics Biotech (NASDAQ: ONCY)
TD Cowen Analyst forecast on ELVN
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/11/26
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Invivyd (IVVD)
Goldman Sachs Analyst forecast on ELVN
Salveen Richter
Goldman Sachs
Goldman Sachs
$41→$59
Buy
22.64%
Upside
Reiterated
06/04/26
Analyst Raises Price Target to $59 and Reaffirms Buy on ELVN-001’s Differentiated CML Opportunity
Mizuho Securities Analyst forecast on ELVN
Salim Syed
Mizuho Securities
Mizuho Securities
$45→$62
Buy
28.87%
Upside
Reiterated
06/02/26
Mizuho Securities Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)
H.C. Wainwright Analyst forecast on ELVN
Robert Burns
H.C. Wainwright
H.C. Wainwright
$56
Buy
16.40%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN), Molina Healthcare (NYSE: MOH) and Aldeyra Therapeutics (NASDAQ: ALDX)
Clear Street Analyst forecast on ELVN
Kaveri Pohlman
Clear Street
Clear Street
$36→$55
Buy
14.32%
Upside
Reiterated
04/27/26
Enliven price target raised to $55 from $36 at Clear StreetEnliven price target raised to $55 from $36 at Clear Street
BTIG Analyst forecast on ELVN
Justin Zelin
BTIG
BTIG
$45
Buy
-6.46%
Downside
Reiterated
08/14/25
BTIG Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Enliven Therapeutics

3 Months
Robert BurnsH.C. Wainwright
Success Rate
8/11 ratings generated profit
73%
Average Return
+8.25%
Copying Robert Burns's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +8.25% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
9/11 ratings generated profit
82%
Average Return
+73.07%
Copying Robert Burns's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +73.07% per trade.
2 Years
Salim SyedMizuho Securities
Success Rate
12/12 ratings generated profit
100%
Average Return
+122.88%
Copying Salim Syed's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +122.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELVN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
2
0
2
6
7
Buy
9
13
19
16
11
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
13
21
22
18
In the current month, ELVN has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ELVN average Analyst price target in the past 3 months is 64.56.
Each month's total comprises the sum of three months' worth of ratings.

ELVN Financial Forecast

ELVN Earnings Forecast

Next quarter’s earnings estimate for ELVN is -$0.39 with a range of -$0.44 to -$0.29. The previous quarter’s EPS was -$0.38. ELVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ELVN has Performed in-line its overall industry.
Next quarter’s earnings estimate for ELVN is -$0.39 with a range of -$0.44 to -$0.29. The previous quarter’s EPS was -$0.38. ELVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ELVN has Performed in-line its overall industry.
No data currently available

ELVN Sales Forecast

Next quarter’s sales forecast for ELVN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ELVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ELVN has Performed in-line its overall industry.
Next quarter’s sales forecast for ELVN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ELVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ELVN has Performed in-line its overall industry.

ELVN Stock Forecast FAQ

What is ELVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Enliven Therapeutics, Inc.’s 12-month average price target is 64.56.
    What is ELVN’s upside potential, based on the analysts’ average price target?
    Enliven Therapeutics, Inc. has 34.18% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ELVN a Buy, Sell or Hold?
          Enliven Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Enliven Therapeutics, Inc.’s price target?
            The average price target for Enliven Therapeutics, Inc. is 64.56. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $80.00 ,the lowest forecast is $55.00. The average price target represents 34.18% Increase from the current price of $48.11.
              What do analysts say about Enliven Therapeutics, Inc.?
              Enliven Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of ELVN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.